- Home
- UTHR
as 07-11-2025 3:37pm EST
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | SILVER SPRING |
| Market Cap: | 14.4B | IPO Year: | 1999 |
| Target Price: | $383.08 | AVG Volume (30 days): | 561.1K |
| Analyst Decision: | Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 25.10 | EPS Growth: | 18.86 |
| 52 Week Low/High: | $266.98 - $417.81 | Next Earning Date: | 07-30-2025 |
| Revenue: | $2,994,100,000 | Revenue Growth: | 19.84% |
| Revenue Growth (this year): | 14.58% | Revenue Growth (next year): | 6.34% |
Stock Insider Trading Activity of United Therapeutics Corporation (UTHR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Giltner Richard | UTHR | Director | Jun 24 '25 | Sell | $289.60 | 3,036 | $879,214.06 | 19,384 | |
| MAHON PAUL A | UTHR | EVP & GENERAL COUNSEL | Jun 12 '25 | Sell | $279.34 | 11,000 | $3,079,514.30 | 36,981 | |
| EDGEMOND JAMES | UTHR | CFO AND TREASURER | Jun 9 '25 | Sell | $326.46 | 12,000 | $3,904,496.07 | 8,118 | |
| EDGEMOND JAMES | UTHR | CFO AND TREASURER | Jun 2 '25 | Sell | $325.94 | 12,000 | $3,909,893.25 | 8,118 | |
| MAHON PAUL A | UTHR | EVP & GENERAL COUNSEL | May 29 '25 | Sell | $314.94 | 11,000 | $3,476,765.35 | 36,981 | |
| MAHON PAUL A | UTHR | EVP & GENERAL COUNSEL | May 15 '25 | Sell | $297.17 | 11,000 | $3,246,149.92 | 36,981 | |
| Thompson Tommy G | UTHR | Director | May 9 '25 | Sell | $305.15 | 2,500 | $762,865.00 | 8,480 | |
| MAHON PAUL A | UTHR | EVP & GENERAL COUNSEL | May 1 '25 | Sell | $299.31 | 11,000 | $3,310,201.49 | 36,981 | |
| DWEK RAYMOND | UTHR | Director | Apr 21 '25 | Sell | $285.57 | 3,000 | $856,710.00 | 1,750 | |
| MAHON PAUL A | UTHR | EVP & GENERAL COUNSEL | Apr 17 '25 | Sell | $282.95 | 11,000 | $3,121,543.06 | 36,981 |
Latest United Therapeutics Corporation News
UTHR Breaking Stock News: Dive into UTHR Ticker-Specific Updates for Smart Investing
Insider Monkey
15 days ago
United Therapeutics Announces World’s First Bioengineered External Liver Treatment in Clinical Study
Zacks
16 days ago
Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last?
Zacks
17 days ago
Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term
Zacks
18 days ago
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
Simply Wall St.
18 days ago
Does United Therapeutics (NASDAQ:UTHR) Deserve A Spot On Your Watchlist?
StockStory
18 days ago
5 Must-Read Analyst Questions From United Therapeutics’s Q1 Earnings Call
Business Wire
19 days ago
United Therapeutics and Intermountain Health Announce the First Patient Treated With External Liver Support Using a Bioengineered Liver
Business Wire
20 days ago
United Therapeutics Corporation Concludes Enrollment of the ADVANCE OUTCOMES Study of Ralinepag for the Treatment of Pulmonary Arterial Hypertension
Compare UTHR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "UTHR United Therapeutics Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.